184 related articles for article (PubMed ID: 35086136)
1. IRF8 is a transcriptional activator of CD37 expression in diffuse large B-cell lymphoma.
Elfrink S; Ter Beest M; Janssen L; Baltissen MP; Jansen PWTC; Kenyon AN; Steen RM; de Windt D; Hagemann PM; Hess C; van Spronsen DJ; Hoevenaars B; van der Spek E; Xu-Monette ZY; Young KH; Kaffa C; Bervoets S; van Heek J; Hesius E; de Winde CM; Vermeulen M; van den Brand M; Scheijen B; van Spriel AB
Blood Adv; 2022 Apr; 6(7):2254-2266. PubMed ID: 35086136
[TBL] [Abstract][Full Text] [Related]
2. High frequency of inactivating tetraspanin
Elfrink S; de Winde CM; van den Brand M; Berendsen M; Roemer MGM; Arnold F; Janssen L; van der Schaaf A; Jansen E; Groenen PJTA; Eijkelenboom A; Stevens W; Hess CJ; van Krieken JH; Vermaat JSP; Cleven AHG; de Groen RAL; Neviani V; de Jong D; van Deventer S; Scheijen B; van Spriel AB
Blood; 2019 Sep; 134(12):946-950. PubMed ID: 31366619
[TBL] [Abstract][Full Text] [Related]
3. Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.
Xu-Monette ZY; Li L; Byrd JC; Jabbar KJ; Manyam GC; Maria de Winde C; van den Brand M; Tzankov A; Visco C; Wang J; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Wang M; Hagemeister FB; Piris MA; Han van Krieken J; Medeiros LJ; Li Y; van Spriel AB; Young KH
Blood; 2016 Dec; 128(26):3083-3100. PubMed ID: 27760757
[TBL] [Abstract][Full Text] [Related]
4. Increased expression of IRF8 in tumor cells inhibits the generation of Th17 cells and predicts unfavorable survival of diffuse large B cell lymphoma patients.
Zhong W; Xu X; Zhu Z; Du Q; Du H; Yang L; Ling Y; Xiong H; Li Q
Oncotarget; 2017 Jul; 8(30):49757-49772. PubMed ID: 28537908
[TBL] [Abstract][Full Text] [Related]
5. PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine.
Arribas AJ; Gaudio E; Napoli S; Yvon Herbaux CJ; Tarantelli C; Bordone RP; Cascione L; Munz N; Aresu L; Sgrignani J; Rinaldi A; Kwee I; Rossi D; Cavalli A; Zucca E; Stussi G; Stathis A; Sloss C; Davids MS; Bertoni F
bioRxiv; 2023 Nov; ():. PubMed ID: 38014209
[TBL] [Abstract][Full Text] [Related]
6. Tetraspanin CD37 protects against the development of B cell lymphoma.
de Winde CM; Veenbergen S; Young KH; Xu-Monette ZY; Wang XX; Xia Y; Jabbar KJ; van den Brand M; van der Schaaf A; Elfrink S; van Houdt IS; Gijbels MJ; van de Loo FA; Bennink MB; Hebeda KM; Groenen PJ; van Krieken JH; Figdor CG; van Spriel AB
J Clin Invest; 2016 Feb; 126(2):653-66. PubMed ID: 26784544
[TBL] [Abstract][Full Text] [Related]
7. IRF8 is associated with germinal center B-cell-like type of diffuse large B-cell lymphoma and exceptionally involved in translocation t(14;16)(q32.33;q24.1).
Tinguely M; Thies S; Frigerio S; Reineke T; Korol D; Zimmermann DR
Leuk Lymphoma; 2014 Jan; 55(1):136-42. PubMed ID: 23573829
[TBL] [Abstract][Full Text] [Related]
8. CD37 expression in follicular lymphoma.
Yoshimura T; Miyoshi H; Shimono J; Nakashima K; Takeuchi M; Yanagida E; Yamada K; Shimasaki Y; Moritsubo M; Furuta T; Kohno K; Ohshima K
Ann Hematol; 2022 May; 101(5):1067-1075. PubMed ID: 35171311
[TBL] [Abstract][Full Text] [Related]
9. Regulation of the germinal center gene program by interferon (IFN) regulatory factor 8/IFN consensus sequence-binding protein.
Lee CH; Melchers M; Wang H; Torrey TA; Slota R; Qi CF; Kim JY; Lugar P; Kong HJ; Farrington L; van der Zouwen B; Zhou JX; Lougaris V; Lipsky PE; Grammer AC; Morse HC
J Exp Med; 2006 Jan; 203(1):63-72. PubMed ID: 16380510
[TBL] [Abstract][Full Text] [Related]
10. Diffuse large B-cell lymphoma microenvironment displays a predominant macrophage infiltrate marked by a strong inflammatory signature.
Serna L; Azcoaga P; Brahmachary M; Caffarel MM; Braza MS
Front Immunol; 2023; 14():1048567. PubMed ID: 37205092
[TBL] [Abstract][Full Text] [Related]
11. The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model.
Beckwith KA; Frissora FW; Stefanovski MR; Towns WH; Cheney C; Mo X; Deckert J; Croce CM; Flynn JM; Andritsos LA; Jones JA; Maddocks KJ; Lozanski G; Byrd JC; Muthusamy N
Leukemia; 2014 Jul; 28(7):1501-10. PubMed ID: 24445867
[TBL] [Abstract][Full Text] [Related]
12. A super-SILAC based proteomics analysis of diffuse large B-cell lymphoma-NOS patient samples to identify new proteins that discriminate GCB and non-GCB lymphomas.
van der Meeren LE; Kluiver J; Rutgers B; Alsagoor Y; Kluin PM; van den Berg A; Visser L
PLoS One; 2019; 14(10):e0223260. PubMed ID: 31603917
[TBL] [Abstract][Full Text] [Related]
13. Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study.
Stathis A; Flinn IW; Madan S; Maddocks K; Freedman A; Weitman S; Zucca E; Munteanu MC; Lia Palomba M
Invest New Drugs; 2018 Oct; 36(5):869-876. PubMed ID: 29453628
[TBL] [Abstract][Full Text] [Related]
14. [Significance of CD37 expression in malignant B cells].
Wang W; Li Y; Gao L; Xu SH; Gong M; Huang FZ; Li ZL; Chen YR; Ma YG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Jun; 22(3):644-7. PubMed ID: 24989269
[TBL] [Abstract][Full Text] [Related]
15. Quantitative proteomics analysis of differentially expressed proteins in activated B-cell-like diffuse large B-cell lymphoma using quantitative proteomics.
Gao HX; Nuerlan A; Abulajiang G; Cui WL; Xue J; Sang W; Li SJ; Niu J; Ma ZP; Zhang W; Li XX
Pathol Res Pract; 2019 Sep; 215(9):152528. PubMed ID: 31324389
[TBL] [Abstract][Full Text] [Related]
16. Loss of IRF8 Inhibits the Growth of Diffuse Large B-cell Lymphoma.
Xu Y; Jiang L; Fang J; Fang R; Morse HC; Ouyang G; Zhou JX
J Cancer; 2015; 6(10):953-61. PubMed ID: 26316891
[TBL] [Abstract][Full Text] [Related]
17. DNA methylation represses IFN-gamma-induced and signal transducer and activator of transcription 1-mediated IFN regulatory factor 8 activation in colon carcinoma cells.
McGough JM; Yang D; Huang S; Georgi D; Hewitt SM; Röcken C; Tänzer M; Ebert MP; Liu K
Mol Cancer Res; 2008 Dec; 6(12):1841-51. PubMed ID: 19074829
[TBL] [Abstract][Full Text] [Related]
18. Fatty acid metabolism in aggressive B-cell lymphoma is inhibited by tetraspanin CD37.
Peeters R; Cuenca-Escalona J; Zaal EA; Hoekstra AT; Balvert ACG; Vidal-Manrique M; Blomberg N; van Deventer SJ; Stienstra R; Jellusova J; Giera M; Hannibal L; Spiekerkoetter U; Ter Beest M; Berkers CR; van Spriel AB
Nat Commun; 2022 Sep; 13(1):5371. PubMed ID: 36100608
[TBL] [Abstract][Full Text] [Related]
19. Methylation changes of SIRT1, KLF4, DAPK1 and SPG20 in B-lymphocytes derived from follicular and diffuse large B-cell lymphoma.
Frazzi R; Zanetti E; Pistoni M; Tamagnini I; Valli R; Braglia L; Merli F
Leuk Res; 2017 Jun; 57():89-96. PubMed ID: 28324774
[TBL] [Abstract][Full Text] [Related]
20. AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML.
Pereira DS; Guevara CI; Jin L; Mbong N; Verlinsky A; Hsu SJ; Aviña H; Karki S; Abad JD; Yang P; Moon SJ; Malik F; Choi MY; An Z; Morrison K; Challita-Eid PM; Doñate F; Joseph IB; Kipps TJ; Dick JE; Stover DR
Mol Cancer Ther; 2015 Jul; 14(7):1650-60. PubMed ID: 25934707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
